<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p83" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_83{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_83{left:341px;bottom:30px;}
#t3_83{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_83{left:377px;bottom:30px;}
#t5_83{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_83{left:540px;bottom:30px;}
#t7_83{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_83{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_83{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_83{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_83{left:285px;bottom:827px;letter-spacing:-0.37px;word-spacing:0.11px;}
#tc_83{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_83{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_83{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_83{left:1116px;bottom:28px;letter-spacing:0.36px;}
#tg_83{left:35px;bottom:361px;}
#th_83{left:45px;bottom:355px;letter-spacing:0.12px;}
#ti_83{left:77px;bottom:355px;letter-spacing:0.08px;word-spacing:-0.02px;}
#tj_83{left:376px;bottom:355px;letter-spacing:0.12px;}
#tk_83{left:406px;bottom:355px;letter-spacing:0.13px;}
#tl_83{left:480px;bottom:355px;}
#tm_83{left:35px;bottom:343px;}
#tn_83{left:45px;bottom:337px;letter-spacing:0.12px;}
#to_83{left:44px;bottom:320px;letter-spacing:0.12px;word-spacing:0.01px;}
#tp_83{left:35px;bottom:308px;}
#tq_83{left:45px;bottom:302px;letter-spacing:0.12px;}
#tr_83{left:44px;bottom:285px;letter-spacing:0.12px;}
#ts_83{left:44px;bottom:267px;letter-spacing:0.12px;word-spacing:0.01px;}
#tt_83{left:840px;bottom:267px;letter-spacing:0.12px;}
#tu_83{left:44px;bottom:249px;letter-spacing:0.11px;word-spacing:0.01px;}
#tv_83{left:44px;bottom:232px;letter-spacing:0.12px;word-spacing:0.01px;}
#tw_83{left:44px;bottom:214px;letter-spacing:0.1px;word-spacing:0.02px;}
#tx_83{left:581px;bottom:214px;letter-spacing:0.08px;word-spacing:-0.01px;}
#ty_83{left:897px;bottom:214px;letter-spacing:0.12px;}
#tz_83{left:44px;bottom:197px;letter-spacing:0.12px;word-spacing:0.01px;}
#t10_83{left:44px;bottom:179px;letter-spacing:0.1px;word-spacing:-0.01px;}
#t11_83{left:44px;bottom:162px;letter-spacing:0.04px;word-spacing:0.08px;}
#t12_83{left:35px;bottom:150px;}
#t13_83{left:45px;bottom:144px;letter-spacing:0.1px;word-spacing:-0.02px;}
#t14_83{left:44px;bottom:126px;letter-spacing:0.13px;}
#t15_83{left:35px;bottom:115px;}
#t16_83{left:45px;bottom:109px;letter-spacing:0.12px;word-spacing:0.01px;}
#t17_83{left:426px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.22px;}
#t18_83{left:753px;bottom:786px;letter-spacing:-0.11px;}
#t19_83{left:36px;bottom:758px;letter-spacing:-0.1px;}
#t1a_83{left:36px;bottom:740px;letter-spacing:-0.1px;word-spacing:-0.13px;}
#t1b_83{left:36px;bottom:721px;}
#t1c_83{left:47px;bottom:721px;letter-spacing:-0.1px;}
#t1d_83{left:36px;bottom:703px;letter-spacing:-0.32px;word-spacing:0.23px;}
#t1e_83{left:42px;bottom:685px;}
#t1f_83{left:59px;bottom:685px;letter-spacing:-0.09px;}
#t1g_83{left:58px;bottom:666px;letter-spacing:-0.09px;}
#t1h_83{left:64px;bottom:648px;}
#t1i_83{left:77px;bottom:648px;letter-spacing:-0.09px;}
#t1j_83{left:934px;bottom:656px;}
#t1k_83{left:42px;bottom:630px;}
#t1l_83{left:59px;bottom:630px;letter-spacing:-0.09px;}
#t1m_83{left:64px;bottom:611px;}
#t1n_83{left:77px;bottom:611px;letter-spacing:-0.09px;}
#t1o_83{left:548px;bottom:619px;}
#t1p_83{left:36px;bottom:575px;letter-spacing:-0.35px;word-spacing:0.23px;}
#t1q_83{left:36px;bottom:556px;letter-spacing:-0.1px;word-spacing:-0.13px;}
#t1r_83{left:36px;bottom:538px;}
#t1s_83{left:47px;bottom:538px;letter-spacing:-0.09px;}
#t1t_83{left:36px;bottom:520px;letter-spacing:-0.09px;}
#t1u_83{left:36px;bottom:501px;letter-spacing:-0.1px;}
#t1v_83{left:42px;bottom:483px;}
#t1w_83{left:59px;bottom:483px;letter-spacing:-0.09px;word-spacing:-0.07px;}
#t1x_83{left:582px;bottom:483px;letter-spacing:-0.1px;}
#t1y_83{left:635px;bottom:483px;}
#t1z_83{left:64px;bottom:465px;}
#t20_83{left:77px;bottom:465px;letter-spacing:-0.09px;}
#t21_83{left:42px;bottom:446px;}
#t22_83{left:59px;bottom:446px;letter-spacing:-0.09px;}
#t23_83{left:64px;bottom:428px;}
#t24_83{left:77px;bottom:428px;letter-spacing:-0.09px;}
#t25_83{left:548px;bottom:436px;}
#t26_83{left:36px;bottom:403px;letter-spacing:-0.1px;}
#t27_83{left:36px;bottom:385px;letter-spacing:-0.11px;word-spacing:0.01px;}
#t28_83{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_83{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_83{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_83{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_83{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_83{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_83{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_83{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_83{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s8_83{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s9_83{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sa_83{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_83{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sc_83{font-size:17px;font-family:Webdings_k6;color:#000;}
.sd_83{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.se_83{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sf_83{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts83" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg83Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg83" style="-webkit-user-select: none;"><object width="1210" height="935" data="83/83.svg" type="image/svg+xml" id="pdf83" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_83" class="t s0_83">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_83" class="t s1_83">® </span>
<span id="t3_83" class="t s0_83">(NCCN </span>
<span id="t4_83" class="t s1_83">® </span>
<span id="t5_83" class="t s0_83">), All rights reserved. NCCN Guidelines </span>
<span id="t6_83" class="t s1_83">® </span>
<span id="t7_83" class="t s0_83">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_83" class="t s2_83">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_83" class="t s2_83">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_83" class="t s3_83">NCCN Guidelines Version 4.2024 </span>
<span id="tb_83" class="t s3_83">Salivary Gland Tumors </span>
<span id="tc_83" class="t s4_83">NCCN Guidelines Index </span>
<span id="td_83" class="t s4_83">Table of Contents </span>
<span id="te_83" class="t s4_83">Discussion </span>
<span id="tf_83" class="t s5_83">SALI-A </span>
<span id="tg_83" class="t s6_83">1 </span>
<span id="th_83" class="t s7_83">See </span><span id="ti_83" class="t s8_83">Principles of Radiation Techniques (RAD-A) </span><span id="tj_83" class="t s7_83">and </span><span id="tk_83" class="t s8_83">Discussion</span><span id="tl_83" class="t s7_83">. </span>
<span id="tm_83" class="t s6_83">2 </span>
<span id="tn_83" class="t s7_83">Neutron therapy was historically considered a promising solution for unresectable salivary gland cancers, but this therapy is currently offered at only one center in the </span>
<span id="to_83" class="t s9_83">United States. Pfister DG, Spencer S, Brizel DM, et al. NCCN Head and Neck Cancers, Version 1.2015. J Natl Compr Canc Netw 2015;13:847-855. </span>
<span id="tp_83" class="t s6_83">3 </span>
<span id="tq_83" class="t s7_83">In general, the reirradiated population of patients with head and neck cancer described in current literature represents a diverse but highly selected group of patients </span>
<span id="tr_83" class="t s7_83">treated in centers where there is a high level of expertise and systems in place for managing acute and long-term toxicities. When the goal of treatment is curative </span>
<span id="ts_83" class="t s7_83">and surgery is not an option, reirradiation strategies can be considered for patients who: develop locoregional failures </span><span id="tt_83" class="t s9_83">or second primaries at ≥6 months after the initial </span>
<span id="tu_83" class="t s9_83">radiotherapy; can receive additional doses of radiotherapy of at least 60 Gy; and can tolerate concurrent chemotherapy. OARs for toxicity should be carefully analyzed </span>
<span id="tv_83" class="t s7_83">through review of dose-volume histograms, and consideration for acceptable doses should be made on the basis of time interval since original radiotherapy, anticipated </span>
<span id="tw_83" class="t s7_83">volumes to be included, and patient's life expectancy. For reirradiation dosing, s</span><span id="tx_83" class="t s8_83">ee Principles of Radiation Techniques (RAD-A)</span><span id="ty_83" class="t s7_83">. Proton therapy can be considered </span>
<span id="tz_83" class="t s7_83">when normal tissue constraints cannot be met by photon-based therapy, or when photon-based therapy causes compromise of standard radiation dosing to tumor or </span>
<span id="t10_83" class="t s7_83">postoperative volumes (Takiar V, Garden AS, Ma D, et al. Reirradiation of head and neck cancers with intensity modulated radiation therapy: Outcomes and analyses. </span>
<span id="t11_83" class="t s7_83">Int J Radiat Oncol Biol Phys 2016;95:1117-1131). </span>
<span id="t12_83" class="t s6_83">4 </span>
<span id="t13_83" class="t s9_83">For doses &gt;70 Gy, some clinicians feel that the fractionation should be slightly modified (eg, &lt;2.0 Gy/fraction for at least some of the treatment) to minimize toxicity. An </span>
<span id="t14_83" class="t s7_83">additional 2–3 doses can be added depending on clinical circumstances. </span>
<span id="t15_83" class="t s6_83">5 </span>
<span id="t16_83" class="t s7_83">Suggest 44–50 Gy in 3D-CRT and sequentially planned IMRT or 54–63 Gy with IMRT dose painting technique (dependent on dose per fraction). </span>
<span id="t17_83" class="t s5_83">PRINCIPLES OF RADIATION THERAPY </span>
<span id="t18_83" class="t sa_83">1,2,3 </span>
<span id="t19_83" class="t s5_83">DEFINITIVE: </span>
<span id="t1a_83" class="t s5_83">RT Alone or Concurrent Systemic Therapy/RT </span>
<span id="t1b_83" class="t s5_83">• </span><span id="t1c_83" class="t sb_83">Photon or photon/electron therapy or highly conformal RT techniques </span>
<span id="t1d_83" class="t s5_83">• PTV: </span>
<span id="t1e_83" class="t sc_83"></span><span id="t1f_83" class="t sb_83" data-mappings='[[94,"fi"]]'>High risk: Primary tumor and involved lymph nodes [this includes possible local subclinical inﬁltration at the primary and at the high-risk </span>
<span id="t1g_83" class="t s5_83">level lymph node(s)] </span>
<span id="t1h_83" class="t sd_83">◊ </span><span id="t1i_83" class="t s5_83">Fractionation: 66 Gy (2.0 Gy/fraction) to 70–70.2 Gy (1.8–2.0 Gy/fraction); daily Monday–Friday in 6–8 weeks </span>
<span id="t1j_83" class="t sa_83">4 </span>
<span id="t1k_83" class="t sc_83"></span><span id="t1l_83" class="t s5_83">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t1m_83" class="t sd_83">◊ </span><span id="t1n_83" class="t s5_83">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t1o_83" class="t sa_83">5 </span>
<span id="t1p_83" class="t s5_83">POSTOPERATIVE RT: </span>
<span id="t1q_83" class="t s5_83">RT Alone or Concurrent Systemic Therapy/RT </span>
<span id="t1r_83" class="t s5_83">• </span><span id="t1s_83" class="t sb_83">Preferred interval between resection and postoperative RT is ≤6 weeks </span>
<span id="t1t_83" class="t s5_83">• Photon or photon/electron therapy </span>
<span id="t1u_83" class="t s5_83">• PTV </span>
<span id="t1v_83" class="t sc_83"></span><span id="t1w_83" class="t s5_83">High risk: Adverse pathologic features such as positive margins (</span><span id="t1x_83" class="t se_83">SALI-3</span><span id="t1y_83" class="t s5_83">) </span>
<span id="t1z_83" class="t sd_83">◊ </span><span id="t20_83" class="t s5_83">60–66 Gy (2.0 Gy/fraction); daily Monday–Friday in 6–7 weeks </span>
<span id="t21_83" class="t sc_83"></span><span id="t22_83" class="t s5_83">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t23_83" class="t sd_83">◊ </span><span id="t24_83" class="t s5_83">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t25_83" class="t sa_83">5 </span>
<span id="t26_83" class="t s5_83">Either IMRT (preferred) or 3D-CRT is recommended. Proton therapy can be considered when normal tissue constraints cannot be met by </span>
<span id="t27_83" class="t s5_83">photon-based therapy, or when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes. </span>
<span id="t28_83" class="t sf_83">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
